Indaptus Therapeutics closes roughly $24M placement

The amended agreement extended each purchaser’s outside date from September 29, 2026, to October 16, 2026, before the placement closed.

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. (INDP) completed a private placement of 20,338,974 shares of common stock for aggregate gross proceeds of approximately $24.0 million, before deducting offering expenses. On October 16, 2026, the company received the full purchase price from each purchaser and stated it will issue the shares in connection with closing.

The Stock Purchase Agreement was dated September 8, 2026. The outside date applicable to each purchaser was extended from September 29, 2026, to October 16, 2026.

Filing Explained

Indaptus received the full purchase price and says it will issue 20,338,974 shares; once issued, those shares will increase the share count and reduce existing holders’ percentage ownership.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Shares in private placement: 20,338,974 shares Aggregate gross proceeds: Approximately $24.0 million Purchaser outside date: September 29, 2026 to October 16, 2026

3 metrics

Shares in private placement 20,338,974 shares Shares the company will issue to the purchasers

Aggregate gross proceeds Approximately $24.0 million Before deducting offering expenses

Purchaser outside date September 29, 2026 to October 16, 2026 Extended under notices and consents

Key Terms

private placement, aggregate gross proceeds, outside date

3 terms

private placement financial

"in a private placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

aggregate gross proceeds financial

"aggregate gross proceeds of approximately $24.0 million"

Aggregate gross proceeds are the total amount of money a company expects to receive from a securities offering or financing before any fees, expenses or deductions are taken out. For investors, this number shows the scale of new capital entering the business—like the size of a fuel tank refill—and helps gauge how much cash will be available to pay debts, fund growth or dilute existing ownership.

outside date financial

"the outside date applicable to each Purchaser"

An outside date is the final contractual deadline by which a planned deal—such as a merger, acquisition, or financing—must be completed; if the transaction hasn’t closed by that date, parties typically gain the right to walk away or trigger agreed remedies. It matters to investors because it sets a clear timetable for when uncertainty should end, and approaching or missing the outside date can raise the chance of deal failure, renegotiation, or changes to valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When was the INDP private placement outside date extended?

The outside date applicable to each purchaser was extended from September 29, 2026, to October 16, 2026. Indaptus completed the placement on October 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 04:39 PM EDT Accepted by SEC EDGAR 10/20/2026 - 04:38 PM EDT Learn about SEC filing dates

false 0001857044 0001857044 2026-10-16 2026-10-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 16, 2026

INDAPTUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40652		86-3158720
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

3 Columbus Circle 15th Floor
New York, New York		10019
(Address of principal executive offices)		(Zip Code)

(646) 427-2727

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		INDP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

As previously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 9, 2026, the Company entered into a Stock Purchase Agreement, dated September 8, 2026 (the “Purchase Agreement”) with the purchasers party thereto (the “Purchasers”), pursuant to which the Company agreed to issue and sell an aggregate of 20,338,974 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share, in a private placement (the “Private Placement”), for aggregate gross proceeds of approximately $24.0 million, before deducting offering expenses.

Subsequently, as reported in the Company’s Current Report on Form 8-K filed with the SEC on September 30, 2026, the Company and the Purchasers entered into notices and consents pursuant to which, among other things, the outside date applicable to each Purchaser under the Purchase Agreement was extended from September 29, 2026 to October 16, 2026.

Item 8.01. Other Events.

On October 16, 2026, the Company completed the Private Placement, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase Agreement, as amended. In connection with the closing of the Private Placement, the Company will issue an aggregate of 20,338,974 Shares to the Purchasers.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 20, 2026

	INDAPTUS THERAPEUTICS, INC.
	By:	/s/ Junyi Dai
	Name:	Junyi Dai
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB